Cadila Healthcare Q3 profit rises 52% to Rs 282 cr

Drug firm Cadila Healthcare reported a 52 percent rise in its consolidated net profit to Rs 281.91 crore for the third quarter ended 31 December 2014 on back of robust sales.

hidden February 10, 2015 14:48:26 IST
Cadila Healthcare Q3 profit rises 52% to Rs 282 cr

New Delhi: Drug firm Cadila Healthcare reported a 52 percent rise in its consolidated net profit to Rs 281.91 crore for the third quarter ended 31 December 2014 on back of robust sales.

Cadila Healthcare Q3 profit rises 52 to Rs 282 cr

ThinkStock

The company had posted a net profit after taxes, minority interest and share of profit/loss of associates of Rs 185.97 crore for the corresponding period of the previous fiscal.

Consolidated total income from operations of the company also rose to Rs 2,189.46 crore for the quarter under consideration as against Rs 1,871.69 crore for the same period year ago, Cadila Healthcare said in a filing to BSE.

During the quarter, the company's business in the US registered a growth of 42 per cent while emerging markets business grew by 23 percent, Cadila Healthcare said.

The company had filed 5 additional abbreviated new drug applications (ANDAs) during the third quarter with the US Food and Drug Administration (USFDA), taking the cumulative ANDA filings to 255, it added.

"During the quarter, the company launched Exemptia, the world's first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis," Cadila Healthcare said.

The group's R&D pipeline which comprises 25 biologics (including novel biologics) is being developed to treat auto immune disorders like arthritis, cancer, infertility and stroke, it added.

Shares of Cadila Healthcare were trading at Rs 1,521.25 per scrip in the afternoon trade on BSE, up 3.09 percent from it's previous close.

PTI

Updated Date:

also read

Zydus Healthcare strengthens US portfolio with 2 ANDA buys from Teva
Business

Zydus Healthcare strengthens US portfolio with 2 ANDA buys from Teva

The company said these ANDAs have been acquired by its 100 per cent subsidiary, Zydus Worldwide DMCC and will be financed through the group's internal accruals

Zydus Cadila gets USFDA nod to market osteoporosis drug; to be manufactured in co's Ahmedabad unit
Business

Zydus Cadila gets USFDA nod to market osteoporosis drug; to be manufactured in co's Ahmedabad unit

The drug Risedronate Sodium delayed-release tablets, used for the treatment of osteoporosis in post-menopausal women.

Zydus gets FDA tentative nod to market anti-diabetic tablets in US
Corporate

Zydus gets FDA tentative nod to market anti-diabetic tablets in US

According to IMS health the estimated sales in 2014 for Glipizide ER tablets is $90.1 million